Myriad Women's Health provides the following resources in select languages:

Myriad PrequelTM Prenatal Screen with AMPLIFYTM Technology

Avoid Unnecessary tradeoffs

Introducing Prequel with AMPLIFY Technology. Demonstrated accuracy across all types of patients with our noninvasive prenatal screen.

Why Myriad Prequel

The Myriad Prequel Prenatal Screen is designed to provide individualized analysis and support for each patient, so you can seamlessly incorporate prenatal genetic screening into your practice. This means more of your patients will benefit from valuable information that can make a difference in health outcomes for families.

Demonstrated accuracy across all types of patients

Prequel’s clinical experience study demonstrates that high sensitivity and specificity can be achieved, without having to fail samples to do so.3

Read our peer-reviewed publication >
Reliable results the first time

Prequel delivers results to 99.9% of patients.3

Superior patient benefits

Patients receive a highly, accurate result early in pregnancy regardless of body habitus, race or ethnicity, reducing patient anxiety and the risk associated with unnecessary invasive procedures.3,4

Know What to Expect

Focused conditions

A primary focus on common aneuploidies, as recommended by societal guidelines1,2 with options for additional screening

View full list >
Expanded Aneuploidy Analysis (EAA)

Analyzes all 22 numbered chromosome pairs to provide additional insights into the health of the pregnancy

Learn more about EAA >
Clear risk assessment

Clarity of your patients’ true risk with individualized positive predictive values (PPV) and residual risk estimates to help inform next steps

Learn more about individualized PPV and residual risk >

Early Insights

Watch this patient story to hear how noninvasive prenatal screening can give a patient like Hannah, early insights into her pregnancy to help prepare her family.

About the Prequel Prenatal Screen

The Myriad Prequel Prenatal Screen is a noninvasive prenatal screen that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for common chromosome abnormalities, such as Down syndrome.

cfDNA screening has been shown to be superior to methods that use maternal age, ultrasound, and serum screening. This results in a lower false-positive rate and false-negative rate.5

The Prequel Prenatal Screen can be ordered together with the Foresight® Carrier Screen and offered to all women, including those with high BMI, an ovum donor or a twin pregnancy.

Prequel Test Details

Conditions covered

Common aneuploidies: Trisomy 21, Trisomy 18, Trisomy 13.
Optional analysis of sex chromosomes, microdeletions, and expanded aneuploidies.

Who to screen

All pregnant women

When to screen

As early as 10 weeks into pregnancy

Sample type

One tube of blood

Turnaround time

Results in ~ 1 week

Methodology

Whole-genome sequencing

Supporting services with
Myriad CompleteTM

Myriad offers the following through Myriad Complete to help seamlessly integrate testing and screening into your practice.

Education

We provide resources to help educate your patients about Myriad products.

Access

We offer a comprehensive program to make genetic products accessible for more of your patients.

Results

We deliver screening and testing results effectively and thoroughly so you can focus on care plans.

Consults

We provide consults from patient educators, who are genetic counselors, tailored to help address any questions your patients may have.

Together, with
Myriad Women's Health

  1. Practice Bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol. 2016;127(5):e123–37.
  2. Noninvasive Prenatal Screening for Fetal Aneuploidy, 2016 Update: A Position Statement of the American College of Medical Genetics and Genomics. Obstetrical and Gynecological Survey. 2017 Jan 1;72(1):6-8.
  3. Hancock et al. (2019) Clinical experience across the fetal-fraction spectrum for a noninvasive prenatal screen with low test-failure
    rate. UOG. doi/pdf/10.1002/uog.21904
  4. Muzzey et al. ( 2019). Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenatal Diagnosis. Doi/abs/10.1002/pd.5603.
  5. Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597.6.Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava  Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012, 119(5):890-901. 
  6. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012, 119(5):890-901. 
  7. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2017;50:302-14. 
  8. Gravholt CH, Juul S, Naeraa RW, Hansen J. Prenatal and postnatal prevalence of Turner’s syndrome : a registry study. BMJ. 1996;312:16-21.  
  9. Illumina, Inc. Analytical Validation of the verifi® prenatal test: Enhanced Test Performance for Detecting Trisomies 21, 18, and 13 and the Option for Classification of Sex Chromosome Status. 2012. 
  10. Liao H, Liu S, Wang H. Performance of non-invasive prenatal screening for fetal aneuploidy in twin pregnancies: a meta-analysis. Prenat Diagn. 2017;37: 874-882. 
  11. Rodis JF, Egan JF, Craffey A, Ciarleglio L, Greenstein RM, Scorza WE. Calculated risk of chromosomal abnormalities in twin gestations. Obstet Gynecol. 1990;76: 1037-1041. 
  12.  Simpson LL. Twin-twin transfusion syndrome. Am J Obstet Gynecol. Elsevier; 2013;208: 3-18. 
  13. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999;13:167-70. 
  14. Snijders RJM, Sebire NJ, Cuckle H, Nicolaides KH. Maternal age and gestation age-specific risks for chromosomal defects. Fetal Diag Ther 1995;10:356-67.